Evaluation of Orally Administered Highly Variable Drugs and Drug Formulations

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Pharmaceutical Research

• Publication date

  1996-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1023/A:1016468018478PMID 8956322
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Assessment of Pharmacokinetics and Safety with Bioequivalence of the Nitroglycerin Sublingual Tablets of Two Formulations in Chinese Healthy Subjects: A Bioequivalence Study

  2025cites this paper
• Pharmacokinetic and clinical comparison of super-bioavailable itraconazole and conventional itraconazole at different dosing in dermatophytosis

  2023cites this paper
• Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with breast, colorectal or gastric cancer under fed condition: A multicentric, randomized, open-label, single-dose, two-period, two-way crossover clinical trial.

  2023cites this paper
• The Global Bioequivalence Harmonisation Initiative (GBHI): Report of the fifth international EUFEPS/AAPS conference.

  2023cites this paper
• Physiological Dynamics in the Upper Gastrointestinal Tract and the Development of Gastrointestinal Absorption Models for the Immediate-Release Oral Dosage Forms in Healthy Adult Human

  2023cites this paper
• In Vitro Predictive Dissolution Test Should Be Developed and Recommended as a Bioequivalence Standard for the Immediate-Release Solid Oral Dosage Forms of the Highly Variable Mycophenolate Mofetil.

  2022cites this paper
• Serum and sebum pharmacokinetics evaluation of a novel formulation of itraconazole in healthy volunteers

  2022cites this paper
• Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology

  2022cites this paper
• Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients with Colorectal or Breast Cancer Under Fed Conditions: A Multicenter, Randomized, Open-Label, Three-Period, and Reference-Replicated Crossover Study

  2021cites this paper
• Pharmacogenetic perspectives in improving pharmacokinetic profiles for efficient bioequivalence trials with highly variable drugs: a review

  2020cites this paper
• Bioequivalence for highly variable drugs: regulatory agreements, disagreements, and harmonization

  2019cites this paper
• Bioequivalence study of two formulations of itraconazole 100 mg capsules in healthy volunteers under fed conditions: a randomized, three-period, reference-replicated, crossover study

  2018cites this paper
• Oral peptide delivery: Translational challenges due to physiological effects

  2018cites this paper
• Perspectives on variability in pharmacokinetics of an oral contraceptive product.

  2017cites this paper
• Testing for bioequivalence of highly variable drugs from TR‐RT crossover designs with heterogeneous residual variances

  2017cites this paper
• Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax® tablets (70 mg) in fasting, healthy volunteers: a randomized, open-label, three-way, reference-replicated crossover study

  2017cites this paper
• Modeling and Simulation in Bioequivalence

  2016cites this paper
• Changes in spatial cognition and brain activity after a single dose of testosterone in healthy women.

  2016cites this paper
• Inflation of Type I Error in the Evaluation of Scaled Average Bioequivalence, and a Method for its Control

  2016cites this paper
• HIGHLY VARIABLE MEDICINES – SPECIFIC ASPECTS OF BIOEQUIVALENCE STUDIES

  2015cites this paper
• Bioequivalence studies in Europe before and after 2010

  2015cites this paper
• Bioequivalence accomplishments, ongoing initiatives, and remaining challenges.

  2014cites this paper
• Adjusted Indirect Treatment Comparison of the Bioavailability of WHO‐Prequalified First‐Line Generic Antituberculosis Medicines

  2014cites this paper
• Bioequivalence of Highly Variable Drugs

  2014cites this paper
• Investigation and Need of Bioequivalence Study: Methodology and Regulatory Requirement

  2014cites this paper
• Biopharmaceutical relevance of dissolution profile comparison: Proposal of a combined approach

  2014cites this paper
• Exploring the relationships between scaled bioequivalence limits and within-subject variability.

  2013cites this paper
• Keeping a critical eye on the science and the regulation of oral drug absorption: a review.

  2013cites this paper
• International Guidelines for Bioequivalence of Systemically Available Orally Administered Generic Drug Products: A Survey of Similarities and Differences

  2013cites this paper
• A EQUIVALÊNCIA FARMACÊUTICA NO CONTEXTO DA INTERCAMBIALIDADE ENTRE MEDICAMENTOS GENÉRICOS E DE REFERÊNCIA: BASES TÉCNICAS E CIENTÍFICAS

  2013cites this paper
• Impact of variability on the choice of biosimilarity limits in assessing follow‐on biologics

  2013influential citation
• Innovative approaches for demonstration of bioequivalence: the US FDA perspective.

  2013cites this paper
• Evaluation of central nervous system depressant activity of Cleome rutidosperma

  2012cites this paper
• The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action.

  2012cites this paper
• Current regulatory approaches of bioequivalence testing

  2012cites this paper
• Individualized, discrete event, simulations provide insight into inter- and intra-subject variability of extended-release, drug products

  2012cites this paper
• Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Generic Drug Products by the US Food and Drug Administration

  2012cites this paper
• Estimating product bioequivalence for highly variable veterinary drugs.

  2012cites this paper
• Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions

  2011cites this paper
• Bioequivalence of Highly Variable Drugs: A Comparison of the Newly Proposed Regulatory Approaches by FDA and EMA

  2011cites this paper
• On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline.

  2011cites this paper
• The effect of variability and carryover on average bioequivalence assessment: A simulation study

  2011cites this paper
• Novel methods to assess bioequivalence

  2011influential citation
• FAILURE OF STATISTICAL METHODS TO PROVE BIOEQUIVALENCE OF MELOXICAM DRUG PRODUCTS. I. PARAMETRIC METHODS

  2011cites this paper
• Assessment of algorithms for the prediction of metabolic drug-drug interactions

  2011cites this paper
• From Drug Delivery Systems to Drug Release, Dissolution, IVIVC, BCS, BDDCS, Bioequivalence and Biowaivers

  2010cites this paper
• DMD # 36103 1 Critique of the two-fold measure of prediction success for ratios : application for the assessment of drug-drug interactions

  2010cites this paper
• Randomized crossover study to assess the inter‐ and intrasubject variability of morning mycophenolic acid concentrations from enteric‐coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients

  2010cites this paper
• Bioanalytical approaches, bioavailability assessment, and bioequivalence study for waiver drugs: In vivo and in vitro perspective

  2010cites this paper
• Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.

  2009cites this paper
• Considering Aspects for the Revision of Current Bioequivalence Guideline

  2009cites this paper
• Evaluation of Bioequivalence for Highly Variable Drugs with Scaled Average Bioequivalence

  2009cites this paper
• Regulatory and study conditions for the determination of bioequivalence of highly variable drugs.

  2009cites this paper
• The effects of common solubilizing agents on the intestinal membrane barrier functions and membrane toxicity in rats.

  2009cites this paper
• Evaluation of Bioequivalence of Highly Variable Drugs

  2008cites this paper
• On equivalence and bioequivalence testing.

  2008influential citation
• Quantitative Bioanalysis in Drug Discovery and Development: Principles and Applications

  2008cites this paper
• Bioavailability and Bioequivalence: Focus on Physiological Factors and Variability

  2008cites this paper
• Evaluating average bioequivalence using methods for high variability drugs: a case study.

  2008influential citation
• Replicate Study Design in Bioequivalency Assessment, Pros and Cons: Bioavailabilities of the Antidiabetic Drugs Pioglitazone and Glimepiride Present in a Fixed‐Dose Combination Formulation

  2007cites this paper
• A Bioequivalence Study of Two Oral Desmopressin Tablet Formulations

  2006cites this paper
• Novel Scaled Bioequivalence Limits with Leveling-off Properties

  2006cites this paper
• The anxiolytic-like effects of Aloysia polystachya (Griseb.) Moldenke (Verbenaceae) in mice.

  2006cites this paper
• In vitro and in vivo Equivalence Studies of Alendronate Monosodium Tablets

  2005cites this paper
• Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off properties.

  2005cites this paper
• Tacrolimus Pharmacokinetics and Dose Monitoring After Lung Transplantation for Cystic Fibrosis and Other Conditions

  2005cites this paper
• Evaluation of Bioequivalence of Highly Variable Drugs Using Clinical Trial Simulations. II: Comparison of Single and Multiple-Dose Trials Using AUC and Cmax

  2004cites this paper
• Novel Scaled Average Bioequivalence Limits Based on GMR and Variability Considerations

  2004cites this paper
• PHARMACOCINETIQUE ET SUIVI THERAPEUTIQUE PHARMACOLOGIQUE DU MYCOPHENOLATE MOFETIL DANS LE TRAITEMENT ANTI-REJET DE GREFFE

  2004cites this paper
• Bayesian Forecasting of Oral Cyclosporin Pharmacokinetics in Stable Lung Transplant Recipients With and Without Cystic Fibrosis

  2003influential citation
• Scaling or wider bioequivalence limits for highly variable drugs and for the special case of C(max).

  2003cites this paper
• Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions

  2003cites this paper
• Statistical aspects of bioequivalence assessment in the pharmaceutical industry.

  2003cites this paper
• Limits for the Scaled Average Bioequivalence of Highly Variable Drugs and Drug Products

  2003cites this paper
• Pharmacogenomic biomarkers.

  2002cites this paper
• Risedronate Pharmacokinetics and Intra- and Inter-Subject Variability Upon Single-Dose Intravenous and Oral Administration

  2001cites this paper
• Pharmacokinetics of Ethionamide Administered under Fasting Conditions or with Orange Juice, Food, or Antacids

  2001cites this paper
• Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers.

  2001cites this paper
• Evaluation of the Bioequivalence of Highly-Variable Drugs and Drug Products

  2001cites this paper
• Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics.

  2001cites this paper
• PhRMA Perspective on Population and Individual Bioequivalence

  2000cites this paper
• On the Heterogeneity of Drug Dissolution and Release

  2000cites this paper
• Management and dosing of warfarin therapy.

  2000cites this paper
• A practical approach for evaluating population and individual bioequivalence.

  2000cites this paper
• Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group.

  1999cites this paper
• Nine-month follow-up of SangCya (Sang-35) in kidney transplant patients after conversion from Sandimmune.

  1999cites this paper
• The effect of dosing regimen on the pharmacokinetics of risedronate.

  1999cites this paper
• What are narrow therapeutic index drugs?

  1998cites this paper
• Bioequivalence: switchability and scaling.

  1998cites this paper
• In Vitro and In Situ Absorption of SDZ-RAD Using a Human Intestinal Cell Line (Caco-2) and a Single Pass Perfusion Model in Rats: Comparison with Rapamycin

  1998cites this paper
• Effects of variability in hepatic clearance on the bioequivalence parameters of a drug and its metabolite: simulations using a pharmacostatistical model.

  1998cites this paper
• Individual bioequivalence--has its time come?

  1998cites this paper
• Optimizing the Absorption of Valspodar, a P‐glycoprotein Modulator, Part II: Quantifying its Pharmacokinetic Variability and Refining the Bioavailability Estimate

  1997cites this paper
• Individual and average bioequivalence of highly variable drugs and drug products.

  1997cites this paper
• Bioequivalence: issues and options.

  1997cites this paper
• Bioequivalence: Issues and Options

  1997cites this paper